VERAXA Biotech AG (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has reached another development milestone in its oncology pipeline. The company announced that its VXA-222 bispecific antibody-drug conjugate (bsADC) program has advanced beyond the discovery phase and into the next stage of development. This milestone reflects continued progress across the company's therapeutic portfolio as it simultaneously expands the intellectual property supporting its next generation of antibody-based cancer therapies.
The advancement marks the successful completion of the discovery portion of VERAXA's collaboration with OmniAb Inc., which began in May 2025 (https://nnw.fm/nIprz). With the discovery work completed, VERAXA will now focus on building the final therapeutic candidate by combining the antibody binders identified through the collaboration with its own proprietary antibody engineering, linker, and conjugation technologies. Although VXA-222 is not based on VERAXA's BiTAC platform, it leverages these core technologies and represents one of the company's more advanced development programs.
In addition to the program update, VERAXA recently expanded its intellectual property portfolio with its first BiTAC-related patent filings, alongside additional patents supporting conjugation chemistry, payloads, and antibody technologies. The company now holds more than 50 granted owned or exclusively licensed patents across 26 patent families in 14 countries, with newly filed applications expected to extend protection into at least 2047. This robust IP position is critical as VERAXA continues building a diversified oncology pipeline spanning bispecific antibody-drug conjugates, T-cell engagers, and engineered antibody formats targeting difficult-to-treat cancers.
The implications of this announcement are significant for VERAXA and the broader oncology community. The advancement of VXA-222 into the next development stage demonstrates the company's ability to execute on its strategic collaborations and internal expertise. By leveraging OmniAb's discovery capabilities and combining them with its own proprietary technologies, VERAXA is positioned to bring novel bispecific ADCs to the clinic, potentially offering more effective and targeted treatment options for patients with challenging cancers.
Furthermore, the expansion of its patent portfolio underscores VERAXA's commitment to protecting its innovations and maintaining a competitive edge in the rapidly evolving field of antibody-based therapeutics. With patents extending to at least 2047, the company secures long-term exclusivity for its technologies, which is essential for attracting partners and investors. The breadth of the portfolio, covering BiTAC, conjugation chemistry, payloads, and antibody technologies, provides a strong foundation for future product development and potential licensing opportunities.
As VERAXA continues to advance its pipeline, investors and stakeholders will be watching closely for further updates on VXA-222 and other programs. The company's focus on difficult-to-treat cancers and its innovative approach to antibody engineering position it as a potential key player in the next generation of cancer therapies. With the recent milestones, VERAXA is not only progressing its lead programs but also reinforcing its intellectual property moat, which could translate into significant long-term value.
